Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.


TSX:GUD - Post by User

Comment by MrMugsyon Dec 16, 2022 1:55pm
133 Views
Post# 35176361

RE:RE:RE:Depreciation/Amortization

RE:RE:RE:Depreciation/AmortizationRegarding this comment specifically ...

"All things being equal, its a very smart move as we pay less tax but have the cashflow to reinvest. It's also totally legal and conservative of management. So, it's great to see."

-------

Yes - totally agree.

It is a smart business move and it helps keep more cash at home.
The other trick that was very useful in the past was to buy assets from defunct companies and grow your losses based on the losses that you acquired in the deals.

Then you have the potential for repurposing drugs in your stable towards other indications - thinking that might be a stategic path for our branded generics (but don't know).

Can they eventually repurpose EXELON for other indications in the 15-16 geographies they have rights to ?

Lots of interesting potential.  Just have to wait for it.


<< Previous
Bullboard Posts
Next >>